Fredrik Kahn

Skåne University Hospital

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2022

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine doses but the point estimate decreased markedly to 54% among those with only two doses. Protection from prior infection was also lower after the transition to BA.2. Booster vaccination seems necessary to maintain sufficient protection.

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Ass. Professor

Linköping University

SWEDEN

View details

Oonagh Shannon

Senior Lecturer

Malmö University

SWEDEN

View details

Ariane Neumann

Lund University

SWEDEN

View details

Louise Bennet

Lund University

SWEDEN

View details

Yana Litins'ka

Lund University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Fredrik Kahn

Research Interests

Explore related searches

Contact this professor

Articles (16)

Barriers and motivators associated with COVID-19 vaccination-a vaccine acceptance scoring system based on a population survey in southern Sweden

Anti-SARS-CoV-2 nucleocapsid antibodies to detect exposure to SARS-CoV-2: results from a prospective cohort study on COVID-19 vaccination

Outcomes of the COVID-19 pandemic in chronic lymphocytic leukemia: focus on the very early period and Omicron era

Cognitive sequelae in post-COVID-syndrome: a Danish-Swedish case-control study

Previous SARS-CoV-2 infections and their impact on the protection from reinfection during the Omicron BA.5 wave – a nested case-control study among vaccinated adults in Sweden

Waning protection after vaccination and prior infection against COVID-19-related mortality over 18 months

Treatment outcome with penicillin G or cloxacillin in penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective cohort study

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities – surveillance results from southern Sweden, July 2021 to January 2022

High level of protection against COVID-19 after two doses of BNT162b2 vaccine in the working age population – first results from a cohort study in Southern Sweden

Surveillance of COVID-19 vaccine effectiveness: a real-time case–control study in southern Sweden

Primary diphtheria immunisation of adolescents and adults with low‐dose vaccine, a survey of historic evidence from the literature

Time to Blood Culture Positivity: An Independent Predictor of Mortality in Streptococcus Pyogenes Bacteremia

Thrombocytopenia with acute ischemic stroke and bleeding in a patient newly vaccinated with an adenoviral vector‐based COVID‐19 vaccine: COMMENT from Gruel et al.: RESPONSE from Kahn et al.

Suggested treatment of serious complications to COVID‐19 vaccination with IdeS, a bacterial antibody‐cleaving enzyme

Collaborators (12)

Carl Bonander

Jonas Björk

Mariam Hassan

Malin Hagstrand Aldman

Anna Bläckberg

Malin Inghammar

Peter Bergman

Mats Fredrikson

Oonagh Shannon

Ariane Neumann

Louise Bennet

Yana Litins'ka

Make your next move.